What is Flibanserin Used For?
Flibanserin is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. 1
Primary Indication
Flibanserin is specifically indicated for premenopausal women experiencing:
- Acquired HSDD: Low sexual desire that developed in women who previously had no problems with sexual desire
- Generalized HSDD: Low desire that is not limited to certain types of stimulation, situations, or partners
- Duration: Symptoms present for at least 6 months that cause marked distress 1, 2
Mechanism and Dosing
Flibanserin works as a 5-HT1A receptor agonist and 5-HT2A receptor antagonist, modulating neurotransmitters involved in sexual desire. The approved dose is 100 mg taken once daily at bedtime 1, 2.
Clinical Context and Efficacy
The drug demonstrates statistically significant but modest clinical benefits. In pooled analyses of pivotal trials involving 2,465 premenopausal women, flibanserin showed 2:
- Increase of approximately 0.5-1 additional satisfying sexual event per month compared to placebo
- Improvements in sexual desire scores and reduction in distress related to low desire
- Benefits generally consistent across various demographic subgroups
Use in Cancer Survivors
ASCO guidelines (2018) state that clinicians may offer flibanserin to premenopausal women with HSDD, though with important caveats 3:
- Flibanserin has not been evaluated in women with a history of cancer or those on endocrine therapy
- The risk/benefit ratio remains uncertain in this population
- Psychosocial/psychosexual counseling should be offered as first-line intervention
Important Safety Considerations
Common adverse effects occur significantly more frequently than placebo 4:
- Dizziness (4-fold increased risk)
- Somnolence (4-fold increased risk)
- Nausea (2.4-fold increased risk)
- Fatigue (1.6-fold increased risk)
Critical contraindications and warnings 1:
- Absolute contraindication with alcohol due to risk of severe hypotension and syncope
- Contraindicated with moderate-to-strong CYP3A4 inhibitors
- Must be taken at bedtime to minimize sedation-related risks
- Requires daily dosing (not taken "as needed")
Clinical Perspective
The FDA approval in 2015 remains somewhat controversial 5, 4. The quality of evidence is graded as "very low," and the clinical significance of the modest improvements must be weighed against the substantial adverse effect profile. Women's global impression of improvement scores indicated only "minimal improvement to no change" 4.
Flibanserin is not approved for postmenopausal women, though some research suggests potential benefit in this population 6. It is also not indicated or approved for use in men 7.
Practical Application
Before prescribing flibanserin:
- Confirm diagnosis of acquired, generalized HSDD of ≥6 months duration
- Rule out other causes of low desire (relationship issues, medications, medical conditions, depression)
- Discuss realistic expectations: approximately one additional satisfying sexual event per month
- Counsel on adverse effects, particularly sedation and dizziness
- Emphasize absolute alcohol avoidance
- Consider psychosocial counseling as first-line or adjunctive therapy
- Recognize this requires long-term daily use (potentially years) for sustained benefit 8